Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a therapy recalcitrant disease characterized by the aberrations in multiple genes that drive pathogenesis and limit therapeutic response. While CDK4/6 represents a downstream target of both KRAS mutation and loss of the CDKN2A tumor suppressor in PDAC, clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarasamy, Vishnu, Ruiz, Amanda, Nambiar, Ram, Witkiewicz, Agnieszka K., Knudsen, Erik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047578/
https://www.ncbi.nlm.nih.gov/pubmed/31745297
http://dx.doi.org/10.1038/s41388-019-1102-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047578/
https://www.ncbi.nlm.nih.gov/pubmed/31745297
http://dx.doi.org/10.1038/s41388-019-1102-1

Ejemplares similares